ATS Forcefield Anti-platelet Technology Continues To Demonstrate Positive Results
Medical News Today
4th November 2008
ATS Medical, Inc. (Nasdaq: ATSI), manufacturer and marketer of state-of-the-art cardiac surgery products and services, announced completion of the final feasibility milestone in the development of the ATS Forcefield(TM) technology. The animal feasibility study has been completed with positive results regarding the inhibition of platelet adhesion on mechanical heart valve prostheses.
4th November 2008
ATS Medical, Inc. (Nasdaq: ATSI), manufacturer and marketer of state-of-the-art cardiac surgery products and services, announced completion of the final feasibility milestone in the development of the ATS Forcefield(TM) technology. The animal feasibility study has been completed with positive results regarding the inhibition of platelet adhesion on mechanical heart valve prostheses.
Latest news:
1st December 2008 -
Researchers Learn That Some 'Good Cholesterol' Isn't Good Enough
1st December 2008 -
New NPS Patient Resource On Infective Endocarditis, Australia
28th November 2008 -
Opportunity to invest in a novel Acoustic Pressure Sensor for medical applications
27th November 2008 -
International Medical Team Announces Patient Results In Adult Stem Cell Clinical Study For Pulmonary Hypertension
27th November 2008 -
Medis And TomTec Launch Joint Cardiac Imaging And Analysis Product
26th November 2008 -
Why Does It Take So Long For A Correct Diagnosis Of Pulmonary Hypertension?
26th November 2008 -
Dramatic JUPITER Findings Fail To Sway Prescribing Behavior, Poll Shows
15th November 2008 -
Statement By Merck & Co., Inc., In Response To The FDA's Update Regarding A Safety Review On Bisphosphonates Including FOSAMAX®
14th November 2008 -
Arsenic May Increase Risks For Cardiovascular Disease At Current Epa-Regulated Drinking Water Standards
14th November 2008 -
High-Normal Phosphate Levels Linked To Early Atherosclerosis
